Japan

In Japan, the Pharmaceuticals and Medical Devices Agency (PMDA) serves as the primary regulatory authority responsible for reviewing and evaluating health products including pharmaceuticals, medical devices, diagnostics, and increasingly digital health solutions. The overarching legal framework is established by the Act on Securing Quality, Efficacy and Safety of Products Including Pharmaceuticals and Medical Devices (PMD Act), which replaced the former Pharmaceutical Affairs Law in 2014. Under this framework, marketing authorization (termed 'Shonin' for pharmaceuticals and Class III/IV devices, and 'Ninsho' for certain medical devices certified by registered certification bodies) must be obtained before any product can be commercialized in Japan. The PMDA conducts scientific review of clinical data, quality documentation, and safety profiles in coordination with the Ministry of Health, Labour and Welfare (MHLW), which ultimately grants official marketing approval. Japan also employs a classification system for medical devices (Class I through IV) and pharmaceuticals that determines the depth and rigor of review required.

All applicants seeking market authorization in Japan must appoint a Marketing Authorization Holder (MAH), which must be a Japan-domiciled legal entity, meaning foreign manufacturers typically partner with a local subsidiary or licensed distributor to hold marketing rights. Submissions generally follow the Common Technical Document (CTD) format in alignment with ICH guidelines, and Japan is an active ICH member, facilitating harmonization with international standards. Japan has undertaken several notable reforms in recent years to address its historically long approval timelines and reduce so-called 'drug lag' and 'device lag' relative to other major markets. These include the introduction of priority review designations, the Sakigake (Breakthrough) designation for innovative products, conditional early approval pathways for regenerative medicine and digital therapeutics, and enhanced parallel scientific advice consultations with the PMDA. Regulatory sandbox provisions under the MHLW also allow digital health and AI-based medical device developers to engage in pre-submission dialogue and phased approval processes.

Japan's public healthcare procurement operates within a highly structured national health insurance (NHI) framework administered by the Ministry of Health, Labour and Welfare (MHLW). Once a product receives marketing authorization, its reimbursement and pricing are determined through the NHI listing process, which is governed by the Central Social Insurance Medical Council (Chuikyo). The Chuikyo sets official reimbursement prices for pharmaceuticals under the NHI drug price list (Yakka Kijun) and for medical devices and diagnostics under the insurance coverage and material price lists. Public hospitals, including national and prefectural institutions, procure health products primarily through government-negotiated or group purchasing arrangements that reference these NHI-listed prices. Biennial drug price revisions (moving toward annual revisions for certain categories) and periodic medical device price reassessments are conducted by the MHLW, creating a tightly regulated pricing environment. Prefectural governments and municipal health authorities manage local hospital procurement within the boundaries set by national NHI reimbursement rules, with limited flexibility for independent pricing.

The private sector plays a significant role in Japan's health product market, as numerous private hospitals, clinics, and pharmacy chains procure products through commercial distributors, often negotiating prices at or below the official NHI reimbursement benchmark. Wholesale distributors (tonya) are central intermediaries in Japan's supply chain, and manufacturers typically engage them to reach both public and private healthcare institutions. Japan is a high-income country and is not a primary recipient of donor-funded procurement channels such as UNICEF Supply Division, the Global Fund, Gavi, or USAID; these multilateral mechanisms do not materially influence the domestic market. However, Japan is itself a major donor and contributor to global health procurement initiatives through the Japan International Cooperation Agency (JICA) and bilateral overseas development assistance (ODA) programs. Regarding local manufacturing preferences, Japan does not enforce explicit domestic manufacturing mandates for market access, but government policy strongly encourages domestic production capacity, particularly for critical medicines, vaccines, and medical countermeasures, as reinforced by supply chain resilience strategies adopted following the COVID-19 pandemic.